

CLAIMS AMENDMENT

1-18. (canceled)

¹
~~19.~~ (currently amended): A method of generating a mammalian immune response directed to 158P1D7 (SEQ ID NO: 657), comprising:
providing an immunogenic composition comprising a ~~T-cell epitope or a B-cell epitope~~ of SEQ ID NO: 657; and
exposing the mammal's immune system to the immunogenic composition whereby an immune response to the ~~immunogenic composition~~ ^{SEQ ID NO: 657} is generated.

20. (canceled)

²
~~21.~~ (currently amended): A method of inducing an immune response to a 158P1D7 protein (SEQ ID NO: 657), comprising:
providing an immunogenic composition comprising a ~~T-cell epitope or a B-cell epitope~~ of SEQ ID NO: 657; and
contacting an ~~immune system T-cell or B~~ antigen presenting cell with the immunogenic composition, whereby an immune response ~~the immune system from T-cell or B-cell to the~~ ^{SEQ ID NO: 657} composition is induced.

³
~~22.~~ (currently amended): The method of claim ²~~21~~, wherein the immune response comprises an ~~induced~~ the antigen-presenting cell presenting an antigen of SEQ ID NO: 657 to a B cell, whereby the induced B cell generates antibodies is induced to generate an antibody that specifically bind to the B-cell epitope of binds to SEQ ID NO: 657.

⁴
~~23.~~ (currently amended): The method of claim ²~~21~~, wherein the immune response comprises an ~~induced~~ the antigen presenting cell presenting an antigen of SEQ ID NO: 657 to a cytotoxic T cell (CTL), whereby the induced CTL kills is induced to kill an autologous cell that expresses the protein encoded by SEQ ID NO: 657.

⁵ ~~24~~.² (currently amended): The method of claim ~~21~~, wherein the immune response comprises ~~an induced~~ the antigen presenting cell presenting an antigen of SEQ ID NO: 657 to a helper T cell (HTL), whereby the ~~induced HTL secretes cytokines that facilitate~~ is induced to secrete a cytokine that facilitates the cytotoxic activity of a CTL or the antibody producing activity of a B cell.

25-66. (canceled)

⁶ ~~67~~.¹ (currently amended): The method of claim ~~19~~, wherein the exposing step comprises administering a nucleotide sequence ~~derived from~~ comprising SEQ ID NO: 656 ~~that encodes the T cell epitope or the B cell epitope of SEQ ID NO: 657.~~

⁷ ~~68~~.¹ (currently amended): The method of claim ~~19~~, wherein the immune response comprises ~~an induced~~ the antigen presenting cell presenting an antigen of SEQ ID NO: 657 to a B cell, whereby the ~~induced B cell generates antibodies that specifically bind~~ is induced to generate an antibody that specifically binds to the protein encoded by SEQ ID NO: 657.

⁸ ~~69~~.¹ (currently amended): The method of claim ~~19~~, wherein the immune response comprises ~~an induced~~ the antigen presenting cell presenting an antigen of SEQ ID NO: 657 to a cytotoxic T cell (CTL), whereby the ~~induced CTL kills~~ is induced to kill an autologous cell that expresses the protein encoded by SEQ ID NO: 657.

⁹ ~~70~~.¹ (currently amended): The method of claim ~~19~~, wherein the immune response comprises ~~an induced~~ the antigen presenting cell presenting an antigen of SEQ ID NO: 657 to a helper T cell (HTL), whereby the ~~induced HTL secretes cytokines that facilitate~~ is induced to secrete a cytokine that facilitates the cytotoxic activity of a CTL or the antibody producing activity of a B cell.